GSK at ESMO 2022
GSK is presenting data that showcases our work to maximise the potential of our oncology portfolio to address unmet needs and improve patient survival. The data will also shed new light on opportunities for our pipeline to deliver the next generation of cancer therapies.
Our work in oncology explores the potential role of innovative areas of research, like synthetic lethality and immuno-oncology, to develop novel cancer medicines, both alone and in combination with other investigational and established agents. We aim to optimise clinical impact and improve outcomes for patients across a variety of tumour types.
At ESMO, we’re sharing data that further characterise the impact of checkpoint inhibition on certain solid tumours, advance the understanding of poly (ADP-ribose) polymerase (PARP) inhibitors and highlight research underway on next-generation immuno-oncology therapies. These, and other presentations, reflect the depth and breadth of our work in oncology.
At GSK, we unite science, technology and talent to get ahead of cancer together. If you are a healthcare professional, you can learn more about our marketed products by selecting your market and the specific GSKPro website on our worldwide directory.
Patient stories
Targeting a better future for multiple myeloma patients
We are driving progress for the multiple myeloma community through new research, therapeutic approaches and programmes. In June, GSK announced the first recipient of the Target the Future Think Tank Challenge grant: the HealthTree Foundation, a non-profit organisation helping patients learn more about their health and become their own best advocates. Their proposal, the “HealthTree Equity and Diversity for Multiple Myeloma Program,” aims to improve access, education and support for underserved communities and minority patients. Target the Future is GSK’s international, multi-year initiative dedicated to advancing innovation and addressing key needs in the multiple myeloma community.
